Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17254029 | USE OF AN EXTRACELLULAR MATRIX (ECM) HYDROGEL AS AN ESOPHAGEAL SUBMUCOSAL FLUID CUSHION | December 2020 | July 2022 | Abandon | 19 | 1 | 0 | No | No |
| 17120042 | CANNABINOID ENRICHED COMPOSITION AND METHOD OF USING | December 2020 | October 2023 | Abandon | 34 | 1 | 1 | No | No |
| 17089469 | COMPOSITIONS AND METHODS OF IMPROVING THE SKIN MICROBIOME | November 2020 | January 2024 | Abandon | 39 | 2 | 1 | No | No |
| 17075486 | SSCF PROCESS FOR SECOND GENERATION ETHANOL PRODUCTION FROM LIGNOCELLULOSIC BIOMASS AND 2G RESIDUAL BIOMASS | October 2020 | July 2024 | Abandon | 44 | 2 | 0 | No | No |
| 17045110 | GENE THERAPY FOR OXIDATIVE STRESS | October 2020 | February 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17043885 | USE AND DELIVERY OF AMMONIA OXIDIZING MICROORGANISMS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | September 2020 | April 2024 | Abandon | 42 | 1 | 0 | No | No |
| 16989701 | HOLDERS FOR BIOREACTOR SENSORS, BIOREACTORS HAVING SUCH HOLDERS, AND METHODS CULTURING BIOLOGICAL MATERIAL | August 2020 | April 2023 | Abandon | 32 | 0 | 1 | No | No |
| 16937451 | METHOD FOR PRODUCING ANTIGEN-SPECIFIC T CELLS | July 2020 | February 2025 | Abandon | 54 | 3 | 1 | No | No |
| 16935639 | TRITURATION DEVICES FOR TISSUE DISAGGREGATION | July 2020 | May 2023 | Abandon | 33 | 0 | 1 | No | No |
| 16892156 | PLURIPOTENT STEM CELL-DERIVED MACROPHAGE CAPABLE OF TARGETING TUMOR CELLS AND PREPARATION METHOD THEREOF | June 2020 | October 2024 | Abandon | 52 | 2 | 1 | No | No |
| 15929579 | BACTERIAL STRAIN COMPOSITIONS AND METHODS OF USING SAME | May 2020 | July 2023 | Abandon | 38 | 1 | 1 | No | No |
| 16648349 | RIBOFLAVINASE ENZYMES AND THEIR USE TO PREVENT OFF FLAVOR IN BREWING | March 2020 | October 2024 | Abandon | 55 | 2 | 1 | No | No |
| 16806404 | Dosing Regimens For The Treatment Of Fabry Disease | March 2020 | October 2023 | Abandon | 43 | 2 | 0 | No | No |
| 16640807 | TRANSPOSON SYSTEM AND METHODS OF USE | February 2020 | November 2023 | Abandon | 44 | 2 | 0 | No | No |
| 16639624 | Methods for Antimicrobial Susceptibility Testing | February 2020 | October 2023 | Abandon | 44 | 3 | 0 | No | No |
| 16635142 | CARDIOSPHERE-DERIVED CELLS AND THEIR EXTRACELLULAR VESICLES FOR TREATMENT AND PREVENTION OF CANCER | January 2020 | May 2024 | Abandon | 51 | 3 | 1 | No | No |
| 16751708 | Stable Bioactive Substances and Methods of Making | January 2020 | April 2023 | Abandon | 38 | 1 | 1 | No | No |
| 16710545 | BIOLOGICAL COMPOSITION FOR DEGRADING PLANT PESTICIDE RESIDUES AND THE APPLICATION THEREOF | December 2019 | January 2024 | Abandon | 49 | 4 | 0 | No | No |
| 16684142 | METHOD FOR TREATMENT OF INFERTILITY, PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INFERTILITY AND METHOD FOR PRODUCING THE SAME | November 2019 | March 2023 | Abandon | 40 | 4 | 0 | Yes | No |
| 16603927 | METHODS FOR IDENTIFYING THE HEALTH STATE OF HYPOPHOSPHATASIA (HPP) PATIENTS | October 2019 | April 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16540934 | Multilayered Vascular Tubes | August 2019 | December 2023 | Abandon | 52 | 4 | 0 | No | No |
| 16532801 | Method of Assessing Liver Triglyceride Levels Using a Body Fluid Sample | August 2019 | December 2021 | Abandon | 28 | 1 | 0 | No | No |
| 16531605 | Platform for Engineered Implantable Tissues and Organs and Methods of Making the Same | August 2019 | July 2024 | Abandon | 59 | 4 | 1 | No | No |
| 16422059 | ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOF | May 2019 | October 2020 | Abandon | 17 | 1 | 1 | No | No |
| 16422045 | ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOF | May 2019 | November 2020 | Abandon | 18 | 1 | 1 | No | No |
| 16422031 | ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOF | May 2019 | October 2020 | Abandon | 17 | 1 | 1 | No | No |
| 16422023 | ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOF | May 2019 | October 2020 | Abandon | 17 | 1 | 1 | Yes | No |
| 16422052 | ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOF | May 2019 | October 2020 | Abandon | 17 | 1 | 1 | No | No |
| 16419904 | Process and Apparatus for Producing Mycelium Biomaterial | May 2019 | April 2024 | Abandon | 59 | 5 | 0 | No | No |
| 16397159 | DETERMINATION OF A CONSTITUENT RELATED PROPERTY OF A MULTI-CONSTITUENT SAMPLE | April 2019 | June 2022 | Abandon | 38 | 2 | 0 | Yes | No |
| 16382443 | METHOD FOR MANUFACTURING A STABLE AQUEOUS SOLUTION OF BETA-AMYLASE, AQUEOUS SOLUTION OBTAINED AND USES THEREOF | April 2019 | August 2022 | Abandon | 40 | 4 | 1 | No | No |
| 16370109 | COMPOSITIONS FOR TREATMENT OF ATROPHIC VAGINITIS, PERI- AND POST-MENOPAUSAL DYSPAREUNIA, AND/OR OOPHORECTOMIZED FEMALES AND TREATMENT METHODS THEREWITH | March 2019 | February 2024 | Abandon | 59 | 5 | 0 | Yes | No |
| 16351045 | METHOD FOR SECOND GENERATION ETHANOL PRODUCTION FROM LIGNOCELLULOSIC BIOMASS | March 2019 | June 2024 | Abandon | 60 | 6 | 0 | Yes | No |
| 16332422 | Lin28a ACTIVATOR AND USE THEREFOR | March 2019 | November 2023 | Abandon | 57 | 4 | 0 | Yes | No |
| 16277571 | Skin Care Compositions | February 2019 | July 2022 | Abandon | 41 | 3 | 0 | No | No |
| 16237933 | COMPOSITIONS AND METHODS FOR TREATING THYROID DISEASE | January 2019 | February 2022 | Abandon | 37 | 4 | 0 | No | No |
| 16313359 | Cell enclosure device and use for same | December 2018 | July 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16216091 | AUTOMATED CELL COLLECTION AND SMEARING | December 2018 | February 2024 | Abandon | 60 | 4 | 0 | No | No |
| 16209544 | COMPOSITION COMPRISING AN ACTIVATED MICROBIAL BIOMASS | December 2018 | June 2022 | Abandon | 42 | 4 | 1 | Yes | No |
| 16173536 | COMPOSITION USEFUL FOR THE PREPARATION OF A SUPPOSITORY | October 2018 | February 2022 | Abandon | 39 | 3 | 1 | No | No |
| 16172606 | ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOF | October 2018 | October 2020 | Abandon | 24 | 1 | 0 | No | No |
| 16094846 | Composition of proenzymes for cancer treatment | October 2018 | November 2024 | Abandon | 60 | 6 | 1 | No | No |
| 16094384 | METHODS OF DEBRIDEMENT OF CHRONIC WOUNDS | October 2018 | October 2024 | Abandon | 60 | 6 | 1 | Yes | Yes |
| 16087028 | Device for Storing Blood and Method for Use Thereof | September 2018 | March 2023 | Abandon | 54 | 0 | 1 | No | No |
| 16129870 | PROTEIN KINASE C INHIBITION TO EXTEND TISSUE PLASMINOGEN ACTIVATOR TREATMENT FOR ISCHEMIC DISEASE | September 2018 | November 2024 | Abandon | 60 | 9 | 1 | Yes | No |
| 16081975 | METHODS FOR EXPERIMENTAL EVOLUTION OF NATURAL AND SYNTHETIC MICROBES | September 2018 | May 2023 | Abandon | 56 | 3 | 1 | No | No |
| 16074936 | COMPOSITIONS AND METHODS FOR PROMOTING SKIN HEALTH | August 2018 | November 2020 | Abandon | 27 | 0 | 1 | No | No |
| 16071340 | BICOMPATIBLE PEPTIDEBIOCOMPATIBLE PEPTIDES FOR INHIBITION OF AGGREGATION OF B-AMYLOID PROTEIN | July 2018 | January 2025 | Abandon | 60 | 3 | 1 | No | No |
| 15973903 | Compositions and Methods for Spine Fusion Procedures | May 2018 | August 2021 | Abandon | 39 | 2 | 0 | No | No |
| 15946524 | New A-PRP Medical Device & Tissue Engineering Composition, Manufacturing Machines And Process | April 2018 | December 2023 | Abandon | 60 | 6 | 1 | Yes | No |
| 15933133 | PACKAGED PROBIOTIC COMPOSITION AND USES THEREOF | March 2018 | June 2020 | Abandon | 27 | 1 | 1 | No | No |
| 15927327 | Novel methods for delivering therapeutic agents to the eye via nasal passages | March 2018 | March 2020 | Abandon | 24 | 2 | 0 | No | No |
| 15761396 | A PROCESS OF PREPARING BUCCAL EPITHELIAL CELL SUSPENSION AND ITS USE | March 2018 | August 2023 | Abandon | 60 | 3 | 1 | Yes | No |
| 15907417 | MATRIX CONSTRUCTION | February 2018 | January 2020 | Abandon | 22 | 2 | 0 | No | No |
| 15862201 | Delivery System and Probiotic Composition for Animals and Plants | January 2018 | June 2024 | Allow | 60 | 2 | 0 | No | Yes |
| 15819843 | METHODS OF TREATING CANCER | November 2017 | August 2020 | Abandon | 32 | 2 | 1 | No | No |
| 15819654 | METHOD FOR TREATMENT OF INFERTILITY, PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INFERTILITY AND METHOD FOR PRODUCING THE SAME | November 2017 | June 2020 | Abandon | 31 | 3 | 1 | Yes | No |
| 15574250 | SMALL SCALE CULTIVATION METHOD FOR SUSPENSION CELLS | November 2017 | July 2021 | Abandon | 44 | 2 | 1 | No | No |
| 15782431 | Dosing Regimens For The Treatment Of Fabry Disease | October 2017 | August 2020 | Abandon | 34 | 3 | 0 | Yes | No |
| 15565874 | HUMAN MILK COMPOSITIONS AND METHODS OF MAKING AND USING SAME | October 2017 | March 2021 | Abandon | 41 | 3 | 1 | No | No |
| 15726232 | HUMAN MILK PERMEATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | October 2017 | July 2023 | Abandon | 60 | 6 | 0 | Yes | No |
| 15554886 | COMPOSITION FOR DIAGNOSING SKIN DAMAGE CAUSED BY FINE DUST, AND COMPOSITION COMPRISING GALANGIN AS ACTIVE INGREDIENT | August 2017 | January 2022 | Abandon | 52 | 5 | 1 | No | No |
| 15684207 | METHOD FOR PREPARING INDUCED MESENCHYMAL STEM CELLS AND IMPROVING MESENCHYMAL STEM CELL'S CHARACTERS AND ITS APPLICATIONS | August 2017 | March 2019 | Abandon | 18 | 1 | 1 | No | No |
| 15596940 | Formulations and Methods of Administration of Cephalotaxines, Including Homoharringtonine | May 2017 | June 2018 | Abandon | 13 | 1 | 0 | No | No |
| 15492171 | REFRACTIVE INDEX MATCHING COMPOSITION FOR BIOLOGICAL TISSUE | April 2017 | November 2018 | Abandon | 19 | 1 | 1 | No | No |
| 15513938 | THREE-DIMENSIONAL BIOPRINTED ARTIFICIAL CORNEA | March 2017 | April 2019 | Abandon | 24 | 2 | 1 | No | No |
| 15464690 | METHOD FOR PREPARING A DEGRADABLE MATERIAL | March 2017 | July 2024 | Abandon | 60 | 8 | 1 | Yes | No |
| 15512003 | MICROFLUIDIC SYSTEM AND METHOD FOR PERFUSION BIOREACTOR CELL RETENTION | March 2017 | October 2019 | Abandon | 32 | 2 | 1 | No | No |
| 15457013 | METHOD FOR REDUCING THE VISCOSITY OF A MICROORGANISM-CONTAINING SUSPENSION OR CONCENTRATE | March 2017 | October 2019 | Abandon | 31 | 1 | 1 | No | No |
| 15447974 | COMPOSITIONS FOR IMPROVEMENT OF BRAIN FUNCTION | March 2017 | May 2021 | Abandon | 50 | 5 | 1 | Yes | No |
| 15436358 | ENHANCEMENT OF SKELETAL MUSCLE STEM CELL ENGRAFTMENT BY DUAL DELIVERY OF VEGF AND IGF-1 | February 2017 | September 2022 | Abandon | 60 | 5 | 1 | No | Yes |
| 15503641 | PETRI DISH AND METHOD FOR THE MICROBIOLOGICAL EXAMINATION OF LIQUIDS BY MEMBRANE FILTRATION | February 2017 | August 2021 | Abandon | 54 | 4 | 1 | No | No |
| 15502006 | METHOD OF PACKAGING AMNIOTIC MEMBRANE | February 2017 | April 2018 | Abandon | 14 | 0 | 1 | No | No |
| 15500658 | DETERMINATION OF A CONSTITUENT RELATED PROPERTY OF A MULTI-CONSTITUENT SAMPLE | January 2017 | January 2020 | Abandon | 35 | 3 | 1 | No | No |
| 15329954 | METHOD FOR CAPTURING RARE CELLS IN BLOOD | January 2017 | January 2020 | Abandon | 36 | 2 | 0 | No | No |
| 15328656 | METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELL LINE FROM MESENCHYMAL STEM CELLS, AND CELL LINE OBTAINED THEREBY | January 2017 | November 2022 | Abandon | 60 | 5 | 1 | No | No |
| 15406210 | DRUG COCKTAIL ANALYSES USING MICROSCALE VORTEX-ASSISTED ELECTROPORATION | January 2017 | March 2022 | Abandon | 60 | 5 | 1 | Yes | No |
| 15404899 | MULTIPURPOSE BIOREACTOR | January 2017 | February 2019 | Abandon | 25 | 1 | 1 | No | No |
| 15400196 | Compositions and Related Methods For Treating Hyperadrenocorticism | January 2017 | January 2021 | Abandon | 48 | 4 | 1 | No | No |
| 15323144 | METHOD FOR PRODUCING OXIDIZED GAMMA-GLUTAMYLCYSTEINE AND OXIDIZED GLUTATHIONE | December 2016 | August 2020 | Abandon | 43 | 2 | 1 | No | No |
| 15394452 | OPTICAL BILIRUBIN SENSOR AND ASSAY | December 2016 | July 2023 | Abandon | 60 | 6 | 1 | No | No |
| 15390878 | METHOD FOR TREATING SPINAL CORD INJURY USING PSA-NCAM POSITIVE NEURAL CELLS | December 2016 | May 2019 | Abandon | 29 | 1 | 1 | No | No |
| 15319079 | METHOD FOR MAUFACTURING A STABLE AQUEOUS SOLUTION OF BETA-AMYLASE, AQUEOUS SOLUTION OBTAINED AND USES THEREOF | December 2016 | December 2019 | Abandon | 36 | 2 | 1 | Yes | Yes |
| 15318953 | TISSUE REGENERATION PROMOTER | December 2016 | February 2020 | Abandon | 38 | 2 | 1 | No | No |
| 15318357 | CULTURED CELL DIFFERENTIATION PROMOTION METHOD AND CULTURED CELL DIFFERENTIATION PROMOTER | December 2016 | November 2020 | Abandon | 47 | 4 | 1 | No | No |
| 15317351 | METHODS OF PROTECTION AGAINST ISCHEMIA REPERFUSION INJURY | December 2016 | November 2019 | Abandon | 35 | 2 | 1 | No | No |
| 15368224 | PHAGE TO TREAT BACTERIA ON SKIN | December 2016 | November 2020 | Abandon | 47 | 4 | 1 | No | No |
| 15316142 | Assay for Oral Inflammation | December 2016 | July 2022 | Abandon | 60 | 6 | 1 | No | No |
| 15362951 | Methods for preventing and/or treating nasal polyps and rhinosinusitis | November 2016 | December 2018 | Abandon | 24 | 2 | 0 | No | No |
| 15356950 | GOLD NANOPARTICLE-BASED HOMOGENEOUS COLORIMETRIC DIAGNOSTIC ASSAY FOR THE DETECTION OF PROTEASES AND PROTEASE INHIBITORS | November 2016 | July 2020 | Abandon | 43 | 2 | 1 | No | No |
| 15309420 | METHOD OF CULTURING CELLS | November 2016 | August 2018 | Abandon | 21 | 0 | 1 | No | No |
| 15308262 | MULTI-CHAMBER CULTURE VESSEL AND CELL CULTURING METHOD | November 2016 | February 2025 | Abandon | 60 | 7 | 1 | No | Yes |
| 15306489 | CULTURE DISH | October 2016 | May 2020 | Abandon | 43 | 3 | 1 | No | No |
| 15292335 | COSMETIC SKIN TREATMENT METHOD | October 2016 | July 2018 | Abandon | 22 | 2 | 0 | No | No |
| 15302373 | INGESTIBLE CAPSULE | October 2016 | October 2019 | Abandon | 36 | 3 | 0 | No | No |
| 15283940 | ARRAY OF AGE-TAILORED NUTRITIONAL FORMULA WITH PROBIOTICS | October 2016 | August 2018 | Abandon | 23 | 1 | 0 | No | No |
| 15281291 | SYSTEMIC, ALLOGENIC STEM CELL THERAPIES FOR TREATMENT OF DISEASES IN ANIMALS | September 2016 | July 2021 | Abandon | 57 | 6 | 0 | Yes | Yes |
| 15126460 | COMPOSITIONS AND METHODS FOR TREATING RETINOPATHY | September 2016 | July 2020 | Abandon | 46 | 7 | 1 | Yes | Yes |
| 15265706 | EFFERVESCENT COMPOSITION IN SOLID FORM FOR USE IN VAGINAL APPLICATIONS FOR THE TREATMENT OF VAGINAL INFECTIONS | September 2016 | December 2019 | Abandon | 39 | 3 | 0 | No | No |
| 15265351 | Skin Care Compositions | September 2016 | May 2019 | Abandon | 32 | 2 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MOSS, NATALIE M.
With a 38.5% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 16.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MOSS, NATALIE M works in Art Unit 1653 and has examined 526 patent applications in our dataset. With an allowance rate of 34.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.
Examiner MOSS, NATALIE M's allowance rate of 34.8% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MOSS, NATALIE M receive 2.71 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by MOSS, NATALIE M is 37 months. This places the examiner in the 31% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +28.4% benefit to allowance rate for applications examined by MOSS, NATALIE M. This interview benefit is in the 75% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 8.4% of applications are subsequently allowed. This success rate is in the 5% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 16.7% of cases where such amendments are filed. This entry rate is in the 21% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 18.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 27% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 51.9% of appeals filed. This is in the 23% percentile among all examiners. Of these withdrawals, 35.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 90.3% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 2.3% of allowed cases (in the 76% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.